- Women who take statins, the common cholesterol-lowering medication, during chemotherapy with anthracyclines for early-stage breast cancer are half as likely to require emergency department visits or hospitalization for heart failure in the 5 years after chemotherapy.
- There was also evidence that women taking statins may have a lower risk of heart failure after receiving the breast cancer medication trastuzumab.
- Anthracyclines are an effective treatment for many women with breast cancer, however, it has an increased risk of heart muscle damage, which has limited their use.
- Researchers say statin use should be encouraged in women starting potentially heart-toxic treatments for early-stage breast cancer if they already have indications to takethem for heart disease prevention. However, clinical trials are still needed to determine whether all women with breast cancer should be prescribed statins during chemotherapy that may harm the heart.
Embargoed until 4 a.m. CT/5 a.m. ET Wed., Jan. 6, 2021
DALLAS, Jan. 6, 2021 — Statins, common cholesterol-lowering medications, may protect women’s hearts from damage caused during chemotherapy for early-stage breast cancer, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
“Two types of cancer medications, anthracyclines and trastuzumab, are effective treatments for many women with breast cancer, however, the risk of heart muscle damage has limited their use, particularly in women who are at higher risk for heart problems because of their age or other medical issues,” said Husam Abdel-Qadir, M.D., Ph.D., lead author of the study, assistant professor of medicine at the University of Toronto’s Institute of Health Policy, Management and Evaluation, and a cardiologist at Women’s College Hospital and the Peter Munk Cardiac Centre, part of the University Health Network in Toronto.
“The mechanisms for these medications are essential to kill breast cancer cells, however, these processes can also damage the cells of the heart muscle, leading to weakening of the heart,” he said.
Previous small studies have suggested that women taking statins may have less heart muscle damage from these types of chemotherapy. The exact mechanisms of how statins protect against the cardiac cell damage remains unknown. It is believed that statins have antioxidative and anti-inflammatory actions.
For the current study, researchers used several administrative health databases in Ontario, Canada, to review the occurrence of heart failure in women ages 66 and older who received anthracyclines or trastuzumab for newly diagnosed early-stage breast cancer between 2007 and 2017. Each woman already taking statins was matched with a peer who was not taking statins as well as a variety of medical and social background factors. The two groups were compared to understand how many required hospitalizations or an emergency room visit for heart failure within the five years after chemotherapy. None had previously been diagnosed with heart failure.
- In the 666 pairs of women (median age 69) treated with anthracyclines, those taking statins were 55% less likely to be treated at the hospital for heart failure (1.2% vs. 2.9%).
- In the 390 pairs of women (median age 71) treated with trastuzumab, those taking statins were 54% less likely to be treated at the hospital for heart failure (2.7% vs. 3.7%), a trend that did not reach statistical significance.
“Our findings support the idea that statins may be a potential intervention for preventing heart failure in patients receiving chemotherapy with anthracyclines and potentially trastuzumab,” Abdel-Qadir said.
This observational study found an association but cannot conclude that there is a cause-and-effect relationship between taking statins and a lower risk of heart failure.
“This study does not conclusively prove statins are protective,” Abdel-Qadir said. “However, this study builds on the body of evidence suggesting that they may have benefits. For women with breast cancer who meet established indications for taking a statin, they should ideally continue taking it throughout their chemotherapy treatment. Women who do not have an indication for a statin should ask their health care team if they can join a clinical trial studying the benefits of statins in protecting against heart muscle damage during chemotherapy. Otherwise, they should focus on measures to optimize their cardiovascular health before, during and after chemotherapy.”
Findings from this study in older women may not be generalizable to younger women or to those at low cardiovascular risk who do not meet current indications for a statin. Because the populations are similar in terms of demographics, these results from Canada are likely generalizable to women in the United States. Other limitations include that the study is a retrospective analysis that relied on administrative data, and the researchers could not account for potentially important factors that were not available, including the heart’s pumping ability and heart biomarkers.
Other co-authors are David Bobrowski, B.H.Sc.; Limei Zhou, Ph.D.; Peter C. Austin, Ph.D.; Oscar Calvillo-Argüelles, M.D.; Eitan Amir, M.D., Ph.D.; and Douglas S. Lee, M.D., Ph.D. Author disclosures are in the manuscript.
The study was funded by the Ted Rogers Centre for Heart Research and the Canadian Cardiovascular Society.
- Multimedia is available on the right column of release: https://newsroom.heart.org/news/statins-may-protect-the-heart-from-chemotherapy-treatment-of-early-breast-cancer?preview=2797608937e8292e896a3763b5edbea6
- After Jan. 6, 2021, view the manuscript online.
- Breast cancer treatments may increase the risk of heart disease
- What women need to know about breast cancer and heart disease
- Watch animation of how statins work
- Rise Above Heart Failure Patient Resources
- Follow AHA/ASA news on Twitter @HeartNews
- Follow news from the Journal of the American Heart Association @JAHA_AHA
Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Bridgette McNeill: Bridgette.McNeill@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org